Results 171 to 180 of about 10,414,754 (372)

Endocervical lavage technique for embryo transfer improves pregnancy outcome in assisted reproductive techniques [PDF]

open access: bronze, 2003
Gautam Allahbadia   +5 more
openalex   +1 more source

Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation

open access: yesMolecular Oncology, EarlyView.
Cyclin D1 overexpression altered the cell adhesion pathway, while cyclin D2 upregulation had less impact on pathway enrichment analysis. Multiple myeloma (MM) patients with cyclin D1 overexpression showed reduced CD56 expression and increased circulating tumor cells (CTC) levels, suggesting that cyclin D1 may contribute to MM cell dissemination ...
Ignacio J. Cardona‐Benavides   +13 more
wiley   +1 more source

Perinatal Outcomes of Monochorionic Twin Pregnancies Conceived Naturally Versus through Assisted Reproductive Techniques. [PDF]

open access: yesJ Clin Med, 2023
Martínez-Varea A   +5 more
europepmc   +1 more source

Menotropins: revisiting the future of controlled ovarian stimulation protocols in assisted reproductive techniques [PDF]

open access: bronze, 2003
Gautam Allahbadia   +5 more
openalex   +1 more source

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

open access: yesMolecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh   +5 more
wiley   +1 more source

Assisted reproductive techniques in patients with Klinefelter syndrome: A critical review [PDF]

open access: bronze, 2004
Dominik Denschlag   +4 more
openalex   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy